Summary slide.png (88.29 kB)
Cost-Utility Analysis of Nivolumab in the Adjuvant Treatment of Melanoma in France
media
posted on 2020-09-11, 15:40 authored by Bruno Bregman, Siguroli Teitsson, Isabella Orsini, François-Emery Cotté, Adenike Amadi, Andriy Moshyk, Stéphane Roze, Anne-Françoise GaudinThe above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.
